Clinical Trial Update: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the efficacy and safety of HB0034 in patients with generalized pustular psoriasis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• HB0034

Snippet

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Conditions: Generalized Pustular Psoriasis (GPP) | Phase 2 | Status: RECRUITING